Lineage Cell Therapeutics, Inc.
AMEX:LCTXBiotechnology
-$0.04 today
- Market cap
- $212.10M
- Beta
- 1.51
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 1.22M
Average 1.19M
LCTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Lineage Cell Therapeutics, Inc.AMEX: LCTX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $4.23M rose 36.0% year over year, behind the +49.9% change in trailing-twelve-month research & development. Sequentially, it fell 48.6% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Research & development amounted to 121.8% of revenue in FY2025, down 9.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +36.0% toward the trailing-twelve-month pace of +49.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 17.73M USD
- Year-over-year change
- +42.2%
- 4-year CAGR
- -15.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.73M | +42.2% |
| FY2024 | 2024-12-31 | 12.47M | -20.6% |
| FY2023 | 2023-12-31 | 15.71M | +12.3% |
| FY2022 | 2022-12-31 | 13.99M | -58.8% |
| FY2021 | 2021-12-31 | 33.91M | — |
Research & Development vs competitors
How LCTX compares with its peers on the latest reported figures
- LCTX's LTM Mar 2026 research & development of $18.85M is the 3rd highest of the 4 companies compared; the peer median is $83.18M.
- Its year-over-year change of +49.9% is the 2nd highest of 4, against a peer median of -13.6%.
- Research & development amounts to 127.5% of revenue for LCTX, versus a peer median of 68.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $97.51M | +180.1% | +53.3% | 81.1% | |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $18.85M | +49.9% | +8.2% | 127.5% | |
| LTM Dec 2025 | $15.03M | -13.6% | -42.3% | 56.6% | |
| Peer median (excluding LCTX) | $83.18M | -13.6% | -0.5% | 68.8% | |
Competitors are the stored peer set for LCTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.9M | 14.7M | 8.95M | 9.5M | 14.56M |
| Cost of Revenue | 1.43M | 728K | 671K | 334K | 845K |
| Gross Profit | 2.47M | 13.98M | 8.27M | 9.17M | 13.71M |
| Gross Margin | 63.4% | 95.0% | 92.5% | 96.5% | 94.2% |
| Research & Development | 33.91M | 13.99M | 15.71M | 12.47M | 17.73M |
| Selling, General & Admin | 18.21M | 22.51M | 17.3M | 18.17M | 18.46M |
| Operating Expenses | 51.68M | 36.5M | 33.01M | 30.64M | 35.49M |
| Depreciation & Amortization | 873K | 727K | 692K | 609K | 699K |
| EBITDA | (42.4M) | (25.09M) | (22.59M) | (17.97M) | (67.95M) |
| EBITDA Margin | -1088.2% | -170.6% | -252.5% | -189.2% | -466.8% |
| Operating Income | (49.21M) | (22.52M) | (24.73M) | (21.48M) | (21.78M) |
| Operating Margin | -1263.1% | -153.2% | -276.5% | -226.1% | -149.6% |
| Interest Income | 2K | 829K | 1.63M | 1.72M | 1.69M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 5.94M | (3.29M) | 1.45M | 2.9M | (46.87M) |
| Income Before Tax | (43.27M) | (25.81M) | (23.28M) | (18.58M) | (68.65M) |
| Pre-Tax Margin | -1110.6% | -175.6% | -260.3% | -195.6% | -471.6% |
| Income Tax Expense | 0 | 541K | (1.8M) | 0 | (5.11M) |
| Net Income | (43.02M) | (26.27M) | (21.49M) | (18.61M) | (63.53M) |
| Net Margin | -1104.2% | -178.7% | -240.2% | -195.9% | -436.5% |
| EPS (Basic) | (0.26) | (0.15) | (0.12) | (0.09) | (0.28) |
| EPS (Diluted) | (0.26) | (0.15) | (0.12) | (0.09) | (0.28) |
| Weighted Avg Shares | 164.5M | 169.79M | 172.66M | 200.19M | 230.12M |
| Weighted Avg Shares (Diluted) | 164.5M | 169.79M | 172.66M | 200.19M | 230.12M |
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
Intrinsic Alpha fair value
Locked
Current Price
$0.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.